A University of Newcastle research team has secured a $940,000 National Health and Medical Research Council (NHMRC) Ideas Grant to examine the role of ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
The following is a summary of “Systematic review and meta-analysis of conventional medical management in a patient population ...
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
It could also come from the spinal cord and nerves or problems with ... an injury there is an underlying cause that requires treatment the pain persists over a long period Medical imaging scans ...
Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...
Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback